RGD Reference Report - A Toll-like receptor 2/6 agonist reduces allergic airway inflammation in chronic respiratory sensitisation to Timothy grass pollen antigens. - Rat Genome Database

Send us a Message



Submit Data |  Help |  Video Tutorials |  News |  Publications |  Download |  REST API |  Citing RGD |  Contact   

A Toll-like receptor 2/6 agonist reduces allergic airway inflammation in chronic respiratory sensitisation to Timothy grass pollen antigens.

Authors: Fuchs, B  Knothe, S  Rochlitzer, S  Nassimi, M  Greweling, M  Lauenstein, HD  Nassenstein, C  Muller, M  Ebensen, T  Dittrich, AM  Krug, N  Guzman, CA  Braun, A 
Citation: Fuchs B, etal., Int Arch Allergy Immunol. 2010;152(2):131-9. Epub 2009 Dec 16.
RGD ID: 4889537
Pubmed: PMID:20016195   (View Abstract at PubMed)
DOI: DOI:10.1159/000265534   (Journal Full-text)

BACKGROUND: The hygiene hypothesis negatively correlates the microbial burden of the environment with the prevalence of T helper type 2 (Th2)-related disorders, e.g. allergy and asthma. This is explained by Th1 triggering through pathogen-associated molecular patterns via Toll-like receptors (TLRs). In this study, the biological effects of a TLR2/6 agonist as a potential treatment of allergic inflammation are explored. METHODS: In a model of chronic allergic airway inflammation induced by intranasal administration of Timothy grass pollen allergen extract, early TLR agonism and/or interferon (IFN)-gamma administration was compared to the therapeutic and immune-modulating effects of dexamethasone with regard to the cellular inflammation and cytokine profiles. RESULTS: Eosinophilic inflammation was clearly reduced by TLR2/6 agonism. This effect was also seen without simultaneous administration of IFN-gamma. However, lymphocyte counts were not affected among the different treatment groups. More precise determination of the lymphocyte-mediated immune reaction showed that TLR2/6 agonism induced neither CD4+foxp3+ regulatory T cells in draining lymph nodes nor a pronounced Th1 immune response. In contrast, dexamethasone reduced both sensitisation as well as allergic inflammation and, in addition, CD11c+ antigen-presenting cells in lymph nodes. Our data clearly point to the potential to rebalance Th2-skewed allergic immune responses by therapeutic TLR2/6 agonist administration. CONCLUSION: The use of the TLR2/6 agonist is a promising therapeutic approach in diseases with an imbalance in T cell responses, such as allergy and asthma.

RGD Manual Disease Annotations    Click to see Annotation Detail View
TermQualifierEvidenceWithReferenceNotesSourceOriginal Reference(s)
Inflammation  ISOTlr2 (Mus musculus)4889537; 4889537associated with Respiratory HypersensitivityRGD 
Inflammation  ISOTlr6 (Mus musculus)4889537; 4889537associated with Respiratory HypersensitivityRGD 
Inflammation  IDA 4889537; 4889537associated with Respiratory HypersensitivityRGD 

Objects Annotated

Genes (Rattus norvegicus)
Tlr2  (toll-like receptor 2)
Tlr6  (toll-like receptor 6)

Genes (Mus musculus)
Tlr2  (toll-like receptor 2)
Tlr6  (toll-like receptor 6)

Genes (Homo sapiens)
TLR2  (toll like receptor 2)
TLR6  (toll like receptor 6)


Additional Information